title: Prognostic implications of human leukocyte antigen class I expression in patients who underwent surgical resection for non-small-cell lung cancer.
abstract: BACKGROUND
  The purpose of the present study was to clarify the prognostic significance of human leukocyte antigen (HLA) class I expression in patients with non-small-cell lung cancer who underwent complete surgical resection.
  
  
  METHODS
  The expression of HLA class I molecules was evaluated in 403 resected NSCLC specimens using immunohistochemistry. The results were scored as the percentage of stained tumor cells and were categorized into three groups: 0%-24% (decreased), 25%-79% (heterogeneous), and 80% or more (normal).
  
  
  RESULTS
  The expression of HLA class I was evaluated in 124 tumors in the normal expression group, 181 tumors in the heterogeneous expression group, and 98 tumors in the decreased expression group. The 5-year survival rate of all patients after surgery according to the HLA class I expression in the normal, heterogeneous, and decreased groups was 76.6%, 65.9%, and 76.1%, respectively. The prognosis was significantly better in the normal expression group than in the heterogeneous group. Normal HLA class I expression also correlated with favorable survival in patients with stage I disease.
  
  
  CONCLUSIONS
  The normal expression of HLA class I was associated with a favorable prognosis compared with the heterogeneous expression group, but no significant difference was observed between the normal expression and decreased expression groups.
authors.affiliation: Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan. hanagiri@med.uoeh-u.ac.jp
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hanagiri
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Shigematsu
authors.forename: Koji
authors.initials: K
authors.lastname: Kuroda
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Baba
authors.forename: Hironobu
authors.initials: H
authors.lastname: Shiota
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Ichiki
authors.forename: Yoshika
authors.initials: Y
authors.lastname: Nagata
authors.forename: Manabu
authors.initials: M
authors.lastname: Yasuda
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Uramoto
authors.forename: Tomoko
authors.initials: T
authors.lastname: So
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Takenoyama
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Tanaka
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000401:mortality / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism / Q000401:mortality / Q000601:surgery*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000401:mortality / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006680:HLA Antigens / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000378:metabolism / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D006680:HLA Antigens